GlaxoSmithKline Capital Expenditures vs Sale Purchase Of Stock Analysis

GSK Stock

1,480 13.00 0.87%

GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC is a good investment. Please check the relationship between GlaxoSmithKline PLC Capital Expenditures and its Sale Purchase Of Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

Capital Expenditures vs Sale Purchase Of Stock

Capital Expenditures vs Sale Purchase Of Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC Capital Expenditures account and Sale Purchase Of Stock. At this time, the significance of the direction appears to have almost no relationship.

The correlation between GlaxoSmithKline PLC's Capital Expenditures and Sale Purchase Of Stock is 0.13. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Sale Purchase Of Stock in the same time period over historical financial statements of GlaxoSmithKline PLC, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Capital Expenditures and Sale Purchase Of Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of GlaxoSmithKline PLC are associated (or correlated) with its Sale Purchase Of Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Sale Purchase Of Stock has no effect on the direction of Capital Expenditures i.e., GlaxoSmithKline PLC's Capital Expenditures and Sale Purchase Of Stock go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by GlaxoSmithKline PLC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of GlaxoSmithKline PLC operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Sale Purchase Of Stock

Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

At present, GlaxoSmithKline PLC's Discontinued Operations is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 26.3 M, whereas Selling General Administrative is forecasted to decline to about 9.3 B.

	2022	2023	2024	2025 (projected)
Interest Expense	852M	775M	644M	480.7M
Depreciation And Amortization	2.1B	2.3B	2.6B	2.7B

Interest Expense Depreciation And Amortization

GlaxoSmithKline PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings
Total Assets		0.9	0.66	0.89	0.5	0.89	0.88	0.98	0.61	0.99	0.36	0.57	0.79	0.7	0.58	0.05	0.94	0.95	0.56	0.64	0.97	0.34	0.91	0.69	0.7	0.13
Short Long Term Debt Total	0.9		0.46	0.8	0.38	0.87	0.98	0.9	0.65	0.89	0.35	0.56	0.76	0.7	0.64	0.0	0.9	0.87	0.58	0.56	0.9	0.19	0.86	0.87	0.69	0.0
Other Current Liab	0.66	0.46		0.82	0.47	0.64	0.49	0.69	0.15	0.64	0.41	0.33	0.57	0.58	0.41	0.18	0.52	0.71	0.14	0.61	0.67	0.69	0.64	0.36	0.59	0.18
Total Current Liabilities	0.89	0.8	0.82		0.33	0.89	0.81	0.93	0.43	0.87	0.47	0.5	0.78	0.72	0.64	0.17	0.81	0.94	0.42	0.74	0.93	0.4	0.86	0.68	0.72	-0.03
Total Stockholder Equity	0.5	0.38	0.47	0.33		0.28	0.39	0.45	0.16	0.49	0.16	0.37	0.49	0.37	0.18	0.19	0.27	0.38	-0.06	0.11	0.31	0.62	0.48	0.2	0.38	0.89
Property Plant And Equipment Net	0.89	0.87	0.64	0.89	0.28		0.82	0.94	0.73	0.84	0.33	0.64	0.88	0.91	0.82	-0.03	0.9	0.96	0.56	0.67	0.94	0.42	0.93	0.69	0.9	-0.17
Net Debt	0.88	0.98	0.49	0.81	0.39	0.82		0.88	0.5	0.88	0.38	0.46	0.71	0.61	0.55	0.06	0.87	0.85	0.53	0.57	0.88	0.21	0.81	0.9	0.61	0.05
Accounts Payable	0.98	0.9	0.69	0.93	0.45	0.94	0.88		0.62	0.95	0.44	0.64	0.84	0.78	0.66	0.13	0.93	0.98	0.57	0.7	0.98	0.38	0.95	0.68	0.78	0.05
Cash	0.61	0.65	0.15	0.43	0.16	0.73	0.5	0.62		0.55	0.1	0.71	0.65	0.74	0.7	-0.25	0.68	0.61	0.56	0.28	0.61	0.05	0.71	0.37	0.73	-0.2
Non Current Assets Total	0.99	0.89	0.64	0.87	0.49	0.84	0.88	0.95	0.55		0.31	0.48	0.73	0.63	0.49	0.0	0.93	0.92	0.54	0.62	0.95	0.31	0.85	0.68	0.63	0.15
Non Currrent Assets Other	0.36	0.35	0.41	0.47	0.16	0.33	0.38	0.44	0.1	0.31		0.6	0.3	0.28	0.28	0.74	0.33	0.36	0.16	0.44	0.41	0.0	0.51	0.34	0.28	0.01
Cash And Short Term Investments	0.57	0.56	0.33	0.5	0.37	0.64	0.46	0.64	0.71	0.48	0.6		0.62	0.67	0.74	0.49	0.56	0.59	0.48	0.39	0.56	0.21	0.82	0.33	0.67	0.05
Net Receivables	0.79	0.76	0.57	0.78	0.49	0.88	0.71	0.84	0.65	0.73	0.3	0.62		0.92	0.79	0.04	0.73	0.88	0.29	0.54	0.79	0.53	0.88	0.54	0.92	0.12
Common Stock Total Equity	0.7	0.7	0.58	0.72	0.37	0.91	0.61	0.78	0.74	0.63	0.28	0.67	0.92		0.89	-0.03	0.69	0.83	0.35	0.58	0.74	0.57	0.86	0.5	1.0	-0.05
Common Stock Shares Outstanding	0.58	0.64	0.41	0.64	0.18	0.82	0.55	0.66	0.7	0.49	0.28	0.74	0.79	0.89		0.14	0.6	0.74	0.36	0.53	0.65	0.43	0.81	0.51	0.88	-0.19
Short Term Investments	0.05	0.0	0.18	0.17	0.19	-0.03	0.06	0.13	-0.25	0.0	0.74	0.49	0.04	-0.03	0.14		-0.03	0.07	0.01	0.23	0.05	0.06	0.25	0.02	-0.03	0.23
Non Current Liabilities Total	0.94	0.9	0.52	0.81	0.27	0.9	0.87	0.93	0.68	0.93	0.33	0.56	0.73	0.69	0.6	-0.03		0.92	0.66	0.61	0.97	0.23	0.86	0.71	0.68	-0.13
Inventory	0.95	0.87	0.71	0.94	0.38	0.96	0.85	0.98	0.61	0.92	0.36	0.59	0.88	0.83	0.74	0.07	0.92		0.54	0.72	0.97	0.44	0.94	0.66	0.82	-0.02
Other Current Assets	0.56	0.58	0.14	0.42	-0.06	0.56	0.53	0.57	0.56	0.54	0.16	0.48	0.29	0.35	0.36	0.01	0.66	0.54		0.32	0.59	-0.12	0.55	0.37	0.34	-0.34
Other Stockholder Equity	0.64	0.56	0.61	0.74	0.11	0.67	0.57	0.7	0.28	0.62	0.44	0.39	0.54	0.58	0.53	0.23	0.61	0.72	0.32		0.69	0.25	0.63	0.38	0.57	-0.19
Total Liab	0.97	0.9	0.67	0.93	0.31	0.94	0.88	0.98	0.61	0.95	0.41	0.56	0.79	0.74	0.65	0.05	0.97	0.97	0.59	0.69		0.31	0.91	0.73	0.73	-0.09
Property Plant And Equipment Gross	0.34	0.19	0.69	0.4	0.62	0.42	0.21	0.38	0.05	0.31	0.0	0.21	0.53	0.57	0.43	0.06	0.23	0.44	-0.12	0.25	0.31		0.42	0.12	0.58	0.41
Total Current Assets	0.91	0.86	0.64	0.86	0.48	0.93	0.81	0.95	0.71	0.85	0.51	0.82	0.88	0.86	0.81	0.25	0.86	0.94	0.55	0.63	0.91	0.42		0.64	0.86	0.07
Short Term Debt	0.69	0.87	0.36	0.68	0.2	0.69	0.9	0.68	0.37	0.68	0.34	0.33	0.54	0.5	0.51	0.02	0.71	0.66	0.37	0.38	0.73	0.12	0.64		0.5	-0.07
Common Stock	0.7	0.69	0.59	0.72	0.38	0.9	0.61	0.78	0.73	0.63	0.28	0.67	0.92	1.0	0.88	-0.03	0.68	0.82	0.34	0.57	0.73	0.58	0.86	0.5		-0.04
Retained Earnings	0.13	0.0	0.18	-0.03	0.89	-0.17	0.05	0.05	-0.2	0.15	0.01	0.05	0.12	-0.05	-0.19	0.23	-0.13	-0.02	-0.34	-0.19	-0.09	0.41	0.07	-0.07	-0.04

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	80.4B	79.1B	60.1B	59.0B	59.5B	33.6B
Short Long Term Debt Total	27.2B	24.2B	21.0B	18.0B	17.0B	11.2B
Other Current Liab	13.2B	14.7B	14.2B	13.8B	14.8B	15.6B
Total Current Liabilities	22.1B	23.7B	22.8B	21.1B	21.7B	11.5B
Total Stockholder Equity	14.6B	15.1B	10.6B	13.3B	13.7B	14.4B
Property Plant And Equipment Net	11.0B	10.7B	9.6B	10.0B	10.1B	7.2B
Net Debt	20.9B	19.9B	17.3B	15.1B	13.1B	8.4B
Accounts Payable	4.4B	4.5B	3.9B	3.7B	3.5B	2.1B
Cash	6.3B	4.3B	3.7B	2.9B	3.9B	2.8B
Non Current Assets Total	60.2B	60.4B	39.4B	40.4B	42.5B	21.5B
Non Currrent Assets Other	1.1B	1.8B	5.3B	634M	898M	1.0B
Cash And Short Term Investments	6.4B	4.3B	7.9B	5.7B	3.9B	3.9B
Net Receivables	5.5B	6.2B	5.5B	5.9B	6.9B	3.9B
Common Stock Shares Outstanding	4.0B	3.2B	4.1B	4.1B	4.1B	3.4B
Liabilities And Stockholders Equity	80.4B	79.1B	60.1B	59.0B	59.5B	33.6B
Non Current Liabilities Total	37.5B	34.1B	27.2B	25.1B	24.7B	14.6B
Inventory	6.0B	5.8B	5.1B	5.5B	5.7B	3.1B
Other Current Assets	1.9B	1.7B	1.4B	1.6B	502M	476.9M
Other Stockholder Equity	3.1B	3.3B	3.7B	3.2B	3.1B	1.8B
Total Liab	59.6B	57.8B	50.1B	46.2B	46.4B	26.1B
Property Plant And Equipment Gross	11.0B	10.7B	9.6B	20.2B	20.6B	21.6B
Total Current Assets	20.2B	18.7B	20.8B	18.6B	17.0B	12.1B
Short Term Debt	3.7B	3.6B	4.0B	2.8B	2.5B	2.2B
Retained Earnings	6.8B	7.9B	4.4B	7.2B	7.8B	8.2B
Accumulated Other Comprehensive Income	1.6B	642M	(48M)	1.6B	1.5B	1.5B
Intangible Assets	29.8B	30.1B	14.3B	14.8B	15.5B	11.6B
Other Liab	13.7B	14.1B	13.5B	10.2B	11.7B	8.0B
Other Assets	5.1B	5.3B	6.9B	6.8B	7.8B	4.3B
Long Term Debt	22.5B	19.8B	16.2B	14.2B	13.7B	13.6B
Good Will	10.6B	10.6B	7.0B	6.8B	7.0B	4.6B
Property Plant Equipment	11.3B	11.0B	10.7B	9.6B	11.1B	9.7B
Current Deferred Revenue	1.8B	1.6B	299M	222M	171M	179.6M
Net Tangible Assets	(30.1B)	(25.8B)	(25.6B)	(10.8B)	(9.7B)	(10.2B)
Short Long Term Debt	3.5B	3.4B	3.8B	2.7B	2.2B	3.7B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

SLDP	Solid Power
RIO	Rio Tinto ADR
SQM	Sociedad Quimica y

Other Information on Investing in GlaxoSmithKline Stock

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

GlaxoSmithKline Capital Expenditures vs Sale Purchase Of Stock Analysis

Capital Expenditures vs Sale Purchase Of Stock

Capital Expenditures vs Sale Purchase Of Stock Correlation Analysis

Correlation Coefficient

Capital Expenditures

Sale Purchase Of Stock

GlaxoSmithKline PLC fundamental ratios Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in GlaxoSmithKline Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Accounts Payable	+ 0.98	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Inventory	+ 0.98	Accounts Payable
Total Liab	+ 0.98	Accounts Payable

Retained Earnings	- 0.34	Other Current Assets
Short Term Investments	- 0.25	Cash
Retained Earnings	- 0.2	Cash
Retained Earnings	- 0.19	Other Stockholder Equity
Retained Earnings	- 0.19	Common Stock Shares Outstanding
Retained Earnings	- 0.17	Property Plant And Equipment Net